February 26, 2024 10:42 AM EST
News Briefing

Mile­stone’s plans to re­sub­mit heart drug; Alvotech’s $166M of­fer; Vac­cine biotech rais­es $11M

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Mile­stone Phar­ma­ceu­ti­cals de­tails plan to re­sub­mit etri­pamil to the FDA in Q2: For its ex­per­i­men­tal treat­ment for parox­ys­mal supraven­tric­u­lar tachy­car­dia, the com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times